Pregnant Mare Serum Gonadotropin (PMSG/eCG)

Pregnant Mare Serum Gonadotropin, now more accurately termed equine Chorionic Gonadotropin (eCG), represents one of the most important reproductive hormones utilized in modern livestock production and breeding programs. This naturally occurring glycoprotein hormone is extracted from the blood serum of pregnant mares during a specific window of gestation, typically between days 40 and 120 of pregnancy when endometrial cup secretion is at its peak. The hormone possesses unique dual biological activity, exhibiting both follicle-stimulating hormone (FSH) and luteinizing hormone (LH) properties, which makes it exceptionally valuable for manipulating reproductive cycles across multiple livestock species.

The mechanism of action of PMSG/eCG centers on its ability to bind to gonadotropin receptors in the ovaries of target animals, stimulating follicular development and maturation. Unlike pituitary-derived FSH, which has a relatively short half-life measured in hours, eCG possesses an extraordinarily long biological half-life of approximately 40 to 120 hours depending on the species. This extended duration of action results from its high sialic acid content and extensive glycosylation, which protect the molecule from rapid metabolic degradation. The prolonged activity allows for single-dose administration in most protocols, simplifying treatment regimens compared to multiple FSH injections.

PMSG/eCG is commercially available as a lyophilized powder that requires reconstitution with sterile diluent before administration. The purified preparations typically contain standardized international units of biological activity, ensuring consistent potency across production batches. Various brand names exist globally, including Folligon and Novormon for general reproductive applications, while combination products such as PG 600 (containing both PMSG and human chorionic gonadotropin) are specifically formulated for swine reproduction. These preparations undergo rigorous quality control testing to verify biological activity and freedom from contaminants.

From a regulatory perspective, PMSG/eCG holds approval for use in food-producing animals across most major agricultural markets, though specific labeled indications may vary by country and manufacturer. The hormone is not classified as a controlled substance but requires veterinary prescription and oversight due to its potent biological effects and the need for proper timing within reproductive management protocols. Producers must maintain appropriate records of use and adhere to any applicable withdrawal periods, though these are generally minimal or nonexistent given the hormone's natural origin and rapid clearance from edible tissues.

The primary labeled indication for PMSG/eCG in livestock production involves the induction and synchronization of estrus in cycling and non-cycling females across multiple species. In cattle operations, the hormone serves as a critical component of fixed-time artificial insemination protocols, allowing producers to breed large numbers of females within a compressed timeframe without the need for estrus detection. This application proves particularly valuable in beef cattle operations where labor for heat detection may be limited, and in dairy operations seeking to optimize reproductive efficiency and calving intervals.

In sheep and goat reproduction, PMSG/eCG plays an essential role in out-of-season breeding programs and estrus synchronization protocols. Small ruminants are seasonally polyestrous, meaning they naturally cycle only during specific times of the year corresponding to decreasing day length. Administration of eCG following progestogen treatment effectively stimulates follicular development and induces fertile estrus outside the natural breeding season, enabling producers to implement accelerated lambing or kidding programs. The hormone is typically administered at progestogen device removal to ensure adequate follicular development for successful ovulation and conception.

Superovulation induction for embryo transfer programs represents another major application of PMSG/eCG, particularly in cattle and small ruminants. By stimulating the development of multiple follicles beyond the normal single ovulation, the hormone enables collection of multiple embryos from genetically superior females. While FSH protocols are more commonly employed in cattle superovulation due to more predictable responses, eCG remains valuable in certain situations and is widely used in sheep and goat embryo transfer programs. The long half-life of eCG can be advantageous or disadvantageous depending on the specific protocol requirements and desired ovarian response.

In swine production, PMSG/eCG finds extensive application in gilt development programs and weaned sow management. The hormone effectively stimulates follicular growth and estrus in prepubertal gilts, allowing for earlier breeding and improved utilization of genetic potential. For weaned sows, particularly those experiencing prolonged weaning-to-estrus intervals, eCG administration can jumpstart follicular development and return to cyclicity. The combination product PG 600, containing both PMSG and hCG, provides both follicular stimulation and an LH surge to optimize ovulation timing in swine reproductive programs.

Extra-label applications of PMSG/eCG include treatment of various forms of reproductive dysfunction in livestock, including cystic ovarian disease, persistent corpus luteum, and ovarian hypoplasia. The hormone's ability to stimulate follicular development makes it useful for reinitiating ovarian activity in animals with quiescent or minimally active ovaries. Veterinarians may incorporate eCG into therapeutic protocols for individual animals with specific reproductive pathology, though such use requires careful consideration of appropriate dosing and timing. In all extra-label applications, a valid veterinarian-client-patient relationship must exist, and appropriate records must be maintained.

Dosing of PMSG/eCG varies significantly by species, intended application, and desired intensity of ovarian response. In cattle, estrus synchronization protocols typically employ doses ranging from 400 to 700 international units (IU) administered as a single intramuscular or subcutaneous injection. The specific dose depends on the cow's body condition, age, and the concurrent use of other synchronization agents such as progestogens, prostaglandins, or GnRH. Lower doses in the 400-500 IU range are generally recommended for beef cattle with adequate body condition, while higher doses may be necessary for thin cattle or those in deep anestrus. For superovulation protocols in cattle, doses typically range from 1,500 to 3,000 IU, though significant variability exists in individual response to treatment.

In sheep and goats, PMSG/eCG is routinely administered at the time of progestogen device removal, with standard doses ranging from 300 to 500 IU for estrus induction and synchronization. Smaller breeds and younger animals generally receive lower doses within this range, while larger breeds or animals intended for superovulation may receive higher doses. For superovulation in small ruminants, doses typically range from 1,000 to 1,500 IU, with careful attention to breed-specific responses. Certain highly prolific breeds such as Romanov sheep may require lower doses to avoid excessive ovarian hyperstimulation and compromised embryo quality.

Swine dosing protocols typically utilize the combination product PG 600, which contains 400 IU of PMSG combined with 200 IU of human chorionic gonadotropin (hCG). This combination provides both follicular stimulation from the PMSG component and an LH-like stimulus from hCG to support final follicular maturation and ovulation. The standard dose for gilt induction is one vial (5 mL) administered intramuscularly, with breeding occurring approximately 5 to 7 days following treatment. For weaned sows, the same dose may be administered at weaning or shortly thereafter to stimulate rapid return to estrus.

Proper administration technique is essential for optimal results with PMSG/eCG therapy. The lyophilized powder must be reconstituted according to manufacturer instructions using the provided sterile diluent, typically bacteriostatic water or physiological saline. Reconstituted solutions should be used promptly and any remaining product refrigerated and used within the timeframe specified by the manufacturer, usually 24 to 48 hours. Injection should be performed using appropriate needle gauge and length for the species and injection site, with careful attention to aseptic technique to prevent injection site reactions or infections.

Integration of PMSG/eCG into comprehensive reproductive management protocols requires careful timing relative to other hormonal treatments. In progestogen-based synchronization protocols, eCG is typically administered 24 to 48 hours before or at the time of progestogen withdrawal, allowing sufficient time for follicular development before the expected estrus. When used with prostaglandin protocols, eCG administration may occur simultaneously with prostaglandin injection or at specific intervals determined by the protocol design. Fixed-time artificial insemination protocols specify precise intervals between hormone administration and breeding, which must be followed carefully for optimal conception rates.

Withdrawal times for PMSG/eCG are minimal in most jurisdictions due to the hormone's natural origin and rapid clearance from the body. In the United States, no withdrawal time is required for meat or milk when the product is used according to label directions. However, producers should verify current regulatory requirements in their specific jurisdiction, as regulations may vary by country and may be subject to change. Documentation of treatment including date, dose, animal identification, and withdrawal period expiration should be maintained as part of routine herd health records.

PMSG/eCG is generally well-tolerated across livestock species when administered at recommended doses and according to established protocols. The most significant potential adverse effect relates to ovarian hyperstimulation, which occurs when the hormone induces development and ovulation of excessive numbers of follicles. This response is more common with higher doses used in superovulation protocols but can occasionally occur even at standard estrus-synchronizing doses, particularly in animals with heightened sensitivity to gonadotropin stimulation. Signs of ovarian hyperstimulation may include enlarged ovaries detectable on rectal palpation, abdominal discomfort, and in severe cases, ovarian cyst formation or luteal dysfunction.

Injection site reactions represent the most commonly observed local adverse effect following PMSG/eCG administration. These reactions typically manifest as transient swelling, firmness, or mild inflammation at the injection site, usually resolving spontaneously within several days without intervention. The incidence and severity of injection site reactions may be influenced by injection technique, product formulation, volume administered, and individual animal factors. Using appropriate needle gauge, ensuring proper injection depth, and avoiding repeated injection at the same site can minimize the occurrence of local reactions.

In cattle specifically, some animals may exhibit behavioral changes following PMSG/eCG administration, including increased restlessness, mounting behavior, or vocalization. These behavioral manifestations reflect the hormonal stimulation of estrus and are generally considered normal physiological responses rather than true adverse effects. However, the intensity of behavioral estrus can vary considerably among individuals, and animals displaying exceptionally vigorous estrous behavior may require management adjustments to prevent injury to themselves or herd mates.

Repeated administration of PMSG/eCG can lead to the development of antibodies against the equine-derived protein, potentially reducing the effectiveness of subsequent treatments. This immunological response, termed refractoriness, is more commonly observed in animals receiving multiple eCG treatments, such as those undergoing repeated superovulation cycles or seasonal breeding programs requiring annual hormone administration. The clinical significance varies among individual animals, with some maintaining adequate response despite antibody development while others show markedly diminished ovarian response to treatment.

Species-specific sensitivities to PMSG/eCG have been documented, with sheep generally showing more consistent responses compared to cattle and goats. Individual variation in response remains a significant challenge in all species, with some animals showing minimal follicular development despite adequate dosing while others exhibit excessive ovarian stimulation. This variability relates to differences in circulating gonadotropin receptor density, body condition, nutritional status, and genetic factors affecting ovarian responsiveness. Producers and veterinarians should anticipate some degree of response variability and adjust expectations and protocols accordingly.

PMSG/eCG administration is contraindicated in animals with known hypersensitivity to equine-derived proteins or any component of the product formulation. Animals that have developed antibody-mediated refractoriness from previous eCG treatments may show reduced response to subsequent administration and alternative synchronization protocols should be considered. A history of severe injection site reactions or systemic allergic responses to prior PMSG/eCG treatments warrants caution, and affected animals may benefit from alternative gonadotropin sources or non-hormonal breeding management approaches.

The use of PMSG/eCG is contraindicated in pregnant animals, as the follicular stimulation and potential induction of ovulation could disrupt pregnancy maintenance. While the risk of pregnancy termination varies by stage of gestation and species, administration during pregnancy serves no therapeutic purpose and should be avoided. Producers must ensure accurate pregnancy diagnosis before initiating synchronization or superovulation protocols that include eCG. In cattle, rectal palpation or ultrasonographic examination should confirm non-pregnant status before treatment.

Animals with significant reproductive tract pathology, including pyometra, severe endometritis, or structural abnormalities of the ovaries or uterus, should not receive PMSG/eCG until the underlying condition has been addressed. The hormone's stimulation of follicular development and estrus is unlikely to result in successful conception when reproductive tract integrity is compromised, and treatment may exacerbate certain conditions. Veterinary examination to assess reproductive soundness prior to hormonal treatment initiation represents prudent practice, particularly in valuable breeding animals or those with reproductive history concerns.

Age and weight restrictions apply to PMSG/eCG use in certain species and contexts. In gilts, the hormone should not be administered until animals have reached appropriate age and weight thresholds for breeding, typically a minimum of 5.5 to 6 months of age and 200 to 230 pounds body weight. Premature hormonal stimulation of underdeveloped animals can result in suboptimal reproductive performance and long-term negative impacts on breeding career longevity. Similarly, young heifers should have achieved adequate physical development before inclusion in synchronization protocols utilizing eCG.

PMSG/eCG is routinely combined with other reproductive hormones in comprehensive synchronization and superovulation protocols, and these intentional combinations are well-established in veterinary reproductive medicine. Concurrent or sequential use with progestogens (progesterone, medroxyprogesterone acetate, or synthetic progestins) represents the most common combination, with the progestogen providing cycle control while eCG stimulates follicular development. This combination forms the foundation of most out-of-season breeding protocols in sheep and goats and various synchronization programs in cattle.

Interactions with prostaglandin F2alpha or its synthetic analogs (dinoprost, cloprostenol) require careful timing consideration. Prostaglandins induce luteolysis and facilitate synchronization of estrus when administered to cycling animals with functional corpora lutea. When used in combination with PMSG/eCG, the timing between hormone administrations significantly impacts protocol effectiveness. Generally, eCG is administered before or concurrent with prostaglandin injection to allow adequate time for follicular development before the prostaglandin-induced decline in progesterone permits estrus expression.

GnRH (gonadotropin-releasing hormone) preparations may be used in conjunction with PMSG/eCG in certain protocols, particularly those designed for fixed-time artificial insemination. The GnRH administration typically follows eCG treatment and serves to induce final follicular maturation and ovulation at a predictable interval. However, the combination of eCG with GnRH-based protocols (such as Ovsynch in cattle) requires careful protocol design, as the FSH-like activity of eCG may alter the ovarian response to subsequent GnRH treatments. Veterinary guidance is essential when modifying standard protocols to incorporate eCG.

The long half-life of PMSG/eCG has important implications for protocol design and potential interactions with subsequent treatments. The persistent biological activity means that ovarian stimulation continues for several days following administration, potentially affecting the response to other hormones administered during this period. This extended activity can be advantageous in ensuring adequate follicular development but may also contribute to ovarian hyperstimulation if additional gonadotropins are administered before eCG activity has declined. Protocols incorporating eCG should account for this prolonged activity when scheduling subsequent hormonal interventions.

Human safety considerations during PMSG/eCG handling and administration require attention to standard precautions for injectable pharmaceutical products. Accidental self-injection poses theoretical risks, particularly for pregnant women or women of childbearing potential, as the gonadotropin activity could potentially affect reproductive function. Personnel handling and administering the product should use appropriate personal protective equipment and exercise care to avoid needlestick injuries. In the event of accidental human exposure, consultation with a healthcare provider is advisable, particularly for pregnant women.

Food safety and residue avoidance considerations for PMSG/eCG are minimal compared to many other veterinary pharmaceuticals due to the hormone's natural origin and rapid biological degradation. However, producers should maintain accurate treatment records including animal identification, treatment date, product used, and dose administered. These records support compliance with food safety regulations and provide documentation in the unlikely event of questions regarding meat or milk quality. Following label directions and any applicable withdrawal periods, even if listed as zero days, demonstrates due diligence in food safety practices.

Environmental considerations for PMSG/eCG relate primarily to proper disposal of unused product, empty containers, and administration equipment. While the hormone itself poses minimal environmental risk due to its protein nature and susceptibility to environmental degradation, syringes, needles, and product containers should be disposed of according to local regulations for veterinary pharmaceutical waste. Reconstituted product that has exceeded its use-by date should be disposed of rather than administered, as potency and sterility cannot be assured.

Antimicrobial resistance is not a direct concern with hormone products like PMSG/eCG; however, responsible use of all veterinary pharmaceuticals supports overall animal health management. The importance of accurate pregnancy diagnosis before treatment, adherence to labeled doses, and proper timing within reproductive protocols ensures that hormone therapy achieves its intended purpose efficiently. Ineffective hormonal treatments due to improper administration waste resources and may delay achievement of reproductive goals.

Maintaining product efficacy requires attention to proper storage, handling, and administration techniques as detailed in product labeling. The biological activity of PMSG/eCG can be compromised by improper storage conditions, excessive temperature exposure, or contamination of reconstituted product. Using product that has lost potency results in inadequate ovarian stimulation and protocol failure. Training personnel in proper handling and administration procedures supports consistent results and represents an investment in reproductive program success.

PMSG/eCG products in lyophilized (freeze-dried) form require storage under refrigeration at temperatures between 2°C and 8°C (36°F to 46°F) to maintain stability and potency throughout the labeled shelf life. The unreconstituted powder should be protected from light and stored in its original packaging until ready for use. Freezing of the lyophilized product should be avoided, as freeze-thaw cycles can affect the structural integrity of the protein and potentially reduce biological activity. Products stored according to label conditions typically maintain potency for 18 to 24 months from manufacture, though specific expiration dates should be verified on individual product containers.

Reconstitution procedures significantly impact product potency and sterility, warranting careful attention to manufacturer instructions. The supplied diluent, typically sterile bacteriostatic water or physiological saline, should be added to the vial containing lyophilized powder using aseptic technique. Gentle swirling facilitates dissolution without damaging the protein structure through excessive agitation or foaming. The reconstituted solution should be clear and free of particulate matter; any cloudiness, discoloration, or visible particles indicates potential contamination or degradation, and such product should not be used.

Once reconstituted, PMSG/eCG solutions have limited stability and must be used promptly or stored appropriately. Most manufacturers specify that reconstituted product should be refrigerated and used within 24 to 48 hours, though some formulations may allow longer storage periods. The reconstituted solution should be protected from light and kept refrigerated between uses. Multi-dose vials require careful attention to prevent contamination during repeated access; using a new sterile needle for each withdrawal and swabbing the rubber stopper with alcohol before each entry reduces contamination risk. Any remaining product beyond the specified use period should be discarded even if visually unchanged.

Species-specific considerations significantly influence PMSG/eCG dosing and protocol design across the various livestock species utilizing this hormone. Cattle generally require higher absolute doses than small ruminants, with dose adjustments based on body weight, body condition score, and reproductive history. Bos indicus cattle (Brahman and Brahman-influenced breeds) typically show different responsiveness compared to Bos taurus breeds, often requiring modified protocols or alternative synchronization approaches. The FSH-like activity of eCG may produce excessive ovarian stimulation in highly fertile breeds, necessitating dose reduction or protocol modification.

Breed-specific sensitivities in sheep deserve particular attention when designing PMSG/eCG protocols. Highly prolific breeds such as Romanov, Finnsheep, or Booroola Merino possess genetic factors affecting ovulation rate and show heightened ovarian sensitivity to gonadotropin stimulation. Standard doses appropriate for conventional meat breeds may produce excessive multiple ovulations in these prolific breeds, resulting in impractical litter sizes, increased pregnancy loss, or compromised lamb viability. Dose reduction of 25% to 50% compared to standard recommendations may be appropriate for highly prolific breeds.

Production type considerations affect protocol design in cattle, particularly the distinction between dairy and beef operations. Dairy cattle typically receive more intensive reproductive management with closer monitoring, allowing for more precise timing of PMSG/eCG administration relative to other protocol components. Beef cattle operations often require protocols designed for minimal handling and fixed-time insemination, influencing the choice of synchronization products and timing. The metabolic demands of lactation in dairy cattle may affect ovarian responsiveness to gonadotropin stimulation, sometimes necessitating dose adjustment or concurrent nutritional management.

Age and developmental stage influence appropriate PMSG/eCG dosing across species. Young animals receiving their first exposure to reproductive hormones may show heightened sensitivity and benefit from conservative initial dosing. Conversely, older animals or those with extended anestrus periods may require higher doses to achieve adequate follicular stimulation. Body condition score serves as an important indicator of likely response, with thin animals often showing reduced ovarian responsiveness while overconditioned animals may exhibit altered hormonal responses. Optimizing body condition before initiating synchronization protocols enhances the likelihood of successful outcomes.

Human chorionic gonadotropin (hCG) represents the most closely related alternative to PMSG/eCG, though with distinct biological properties affecting clinical applications. While eCG exhibits both FSH and LH activity with an extended half-life, hCG possesses primarily LH-like activity with a shorter duration of action. These differences make hCG more suitable for inducing ovulation following adequate follicular development rather than initiating follicular growth. The combination product PG 600, containing both PMSG and hCG, leverages the complementary activities of both hormones for swine reproductive applications.

Pituitary-derived follicle-stimulating hormone (FSH) preparations offer an alternative approach to ovarian stimulation, particularly for superovulation protocols requiring more precise control of follicular development. FSH products require multiple injections over several days due to their short half-life, but this characteristic allows for more refined manipulation of follicular development compared to the sustained stimulation from eCG. In cattle superovulation for embryo transfer, FSH protocols generally produce more consistent results with better embryo quality compared to single-dose eCG treatment, though at greater expense and labor requirements.

GnRH (gonadotropin-releasing hormone) products such as gonadorelin, buserelin, and deslorelin stimulate endogenous gonadotropin release from the pituitary gland rather than providing exogenous gonadotropins directly. These products find primary application in ovulation induction and corpus luteum manipulation rather than follicular development stimulation. GnRH-based protocols (Ovsynch, Co-synch) represent the dominant synchronization approach in dairy cattle, while combinations of GnRH with eCG offer alternatives for specific situations such as anestrus treatment or out-of-season breeding where additional follicular stimulation is beneficial.